- Home
- FPAY vs BCTXW Comparison
FPAY vs BCTXW Comparison
Compare FPAY & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FPAY
- BCTXW
- Stock Information
- Founded
- FPAY 2003
- BCTXW N/A
- Country
- FPAY United States
- BCTXW Canada
- Employees
- FPAY N/A
- BCTXW N/A
- Industry
- FPAY Diversified Commercial Services
- BCTXW Biotechnology: Pharmaceutical Preparations
- Sector
- FPAY Consumer Discretionary
- BCTXW Health Care
- Exchange
- FPAY Nasdaq
- BCTXW Nasdaq
- Market Cap
- FPAY N/A
- BCTXW N/A
- IPO Year
- FPAY N/A
- BCTXW N/A
- Fundamental
- Price
- FPAY $1.60
- BCTXW $0.12
- Analyst Decision
- FPAY Strong Buy
- BCTXW
- Analyst Count
- FPAY 2
- BCTXW 0
- Target Price
- FPAY $3.25
- BCTXW N/A
- AVG Volume (30 Days)
- FPAY 161.4K
- BCTXW 90.9K
- Earning Date
- FPAY 03-31-2025
- BCTXW 03-14-2025
- Dividend Yield
- FPAY N/A
- BCTXW N/A
- EPS Growth
- FPAY N/A
- BCTXW N/A
- EPS
- FPAY N/A
- BCTXW N/A
- Revenue
- FPAY $134,563,007.00
- BCTXW N/A
- Revenue This Year
- FPAY $25.78
- BCTXW N/A
- Revenue Next Year
- FPAY $6.46
- BCTXW N/A
- P/E Ratio
- FPAY N/A
- BCTXW N/A
- Revenue Growth
- FPAY 24.46
- BCTXW N/A
- 52 Week Low
- FPAY $0.97
- BCTXW $0.10
- 52 Week High
- FPAY $2.37
- BCTXW $0.13
- Technical
- Relative Strength Index (RSI)
- FPAY 51.49
- BCTXW N/A
- Support Level
- FPAY $1.50
- BCTXW N/A
- Resistance Level
- FPAY $1.80
- BCTXW N/A
- Average True Range (ATR)
- FPAY 0.12
- BCTXW 0.00
- MACD
- FPAY 0.02
- BCTXW 0.00
- Stochastic Oscillator
- FPAY 57.45
- BCTXW 0.00
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.